Baba Sy, in Anchorage, AK - Chore Provider

Baba Sy, is a Chore Provider based in Anchorage, Alaska. Baba Sy is licensed to practice in Alaska (license number ) and his current practice location is 3760 W 74th Ave, Anchorage, Alaska. He can be reached at his office (for appointments etc.) via phone at (907) 350-0061.

NPI number for Baba Sy is 1417389511 and his current mailing address is 2025 E 73rd Ave Apt 1, Anchorage, Alaska. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1417389511.

Contact Information

	Baba Sy,
	3760 W 74th Ave, Anchorage, AK 99502-2862
	(907) 350-0061
	(907) 868-1592

Healthcare Provider's Profile

Full Name	Baba Sy
Gender	Male
Speciality	Chore Provider
Location	3760 W 74th Ave, Anchorage, Alaska
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1417389511
Provider Enumeration Date: 07/31/2013
Last Update Date: 07/14/2020

Medical Identifiers

Medical identifiers for Baba Sy such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1417389511	NPI	-	NPPES
1417389511	Medicaid	AK

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103TA0700X	Psychologist - Adult Development & Aging	978570 (Alaska)	Secondary
372500000X	Chore Provider	(Alaska)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Baba Sy is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Baba Sy, 2025 E 73rd Ave Apt 1, Anchorage, AK 99507-2789 Ph: (907) 222-6855	Baba Sy, 3760 W 74th Ave, Anchorage, AK 99502-2862 Ph: (907) 350-0061

News Archive

Using topical non-steroidal anti-inflammatory drugs to relieve the pain of osteoarthritis is only beneficial for the first two weeks

Using topical non-steroidal anti-inflammatory drugs (NSAIDS) to relieve the pain of osteoarthritis is only beneficial for the first two weeks, finds a study available on bmj.com today.

Infection control, widespread testing help reduce SARS-CoV-2 transmission in schools, study finds

Now, a team of researchers at the New York University Grossman School of Medicine explored which school policies had the most significant impact on reducing the risk of in-school SARS-CoV-2 transmission.

Navigating Cancer creates new application to help patients manage, update medical history

Navigating Cancer is putting the power of cancer treatment advocacy and management into the hands of cancer patients. The free website, which empowers cancer patients to take an active role in their care and partner more closely with their physicians during treatment, has created a unique medical history form that enables patients to manage and update their medical history on demand.

Perfectionism drives depression in bipolar/anxiety comorbidity

People with comorbid bipolar spectrum disorders and anxiety tend to display higher levels of depressive symptoms than their counterparts with BSD alone, say researchers.

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

Baba Sy, - in Anchorage, AK